|
40 Companies |
|
51 Products |
|
51 Products |
|
0 Mechanisms of Action |
|
20 Trials |
|
425 News |
|
| «12345678» |
- Trial primary completion date, HEOR: Decision Aid for Therapeutic Options In Sickle Cell Disease (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=120, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2016 --> Jul 2017
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed, Trial primary completion date: Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders (clinicaltrials.gov) - Jan 30, 2017
P2, N=42, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Dec 2016 --> Jul 2017 Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> May 2018
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion, Enrollment change: Sickle Cell Disease Conditioning for Bone Marrow Transplant (clinicaltrials.gov) - Jan 26, 2017
P1, N=8, Completed, Sponsor: Emory University
Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> May 2018 Suspended --> Completed | N=24 --> 8
- Enrollment change, Trial withdrawal, Trial primary completion date: Androgen Regulation of Priapism in Sickle Cell Disease (clinicaltrials.gov) - Jan 19, 2017
P=N/A, N=0, Withdrawn, Sponsor: Johns Hopkins University
Suspended --> Completed | N=24 --> 8 N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2017 --> Jan 2016
- Enrollment change, Trial withdrawal, Trial primary completion date: Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study (clinicaltrials.gov) - Dec 23, 2016
P=N/A, N=0, Withdrawn, Sponsor: University Hospitals Cleveland Medical Center
N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2017 --> Jan 2016 N=50 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2015 --> Dec 2016
- Trial primary completion date: MEMREAD: Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease (clinicaltrials.gov) - Dec 21, 2016
P=N/A, N=99, Recruiting, Sponsor: St. Jude Children's Research Hospital
N=50 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2015 --> Dec 2016 Trial primary completion date: Apr 2017 --> Apr 2018
- | ticagrelor / Generic mfg.
Enrollment closed: HESTIA 1: A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease (clinicaltrials.gov) - Dec 13, 2016
P2, N=40, Active, not recruiting, Sponsor: AstraZeneca
Trial primary completion date: Apr 2017 --> Apr 2018 Recruiting --> Active, not recruiting
- Enrollment change: Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease (clinicaltrials.gov) - Nov 16, 2016
P=N/A, N=22, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Active, not recruiting N=10 --> 22
- budesonide inhalation suspension / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Nov 8, 2016
P1, N=30, Active, not recruiting, Sponsor: Vanderbilt University
N=10 --> 22 Recruiting --> Active, not recruiting | N=20 --> 30 | Trial primary completion date: Sep 2016 --> Dec 2016
- Enrollment closed, Trial initiation date, Trial primary completion date: PArTNER: PATient Navigator to rEduce Readmissions (clinicaltrials.gov) - Oct 31, 2016
P=N/A, N=1300, Active, not recruiting, Sponsor: University of Illinois at Chicago
Recruiting --> Active, not recruiting | N=20 --> 30 | Trial primary completion date: Sep 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Initiation date: Oct 2014 --> Jul 2014 | Trial primary completion date: Apr 2016 --> Dec 2016
- | PF-04447943 / Pfizer
Trial completion, Enrollment change: Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease (clinicaltrials.gov) - Oct 31, 2016
P1b, N=30, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Initiation date: Oct 2014 --> Jul 2014 | Trial primary completion date: Apr 2016 --> Dec 2016 Recruiting --> Completed | N=64 --> 30
- ||||||| vepoloxamer (MST-188) / Savara
Trial completion: Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) (clinicaltrials.gov) - Oct 28, 2016
P3, N=388, Completed, Sponsor: Mast Therapeutics, Inc.
Recruiting --> Completed | N=64 --> 30 Recruiting --> Completed
- Enrollment closed: CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant (clinicaltrials.gov) - Oct 5, 2016
P2, N=35, Active, not recruiting, Sponsor: New York Medical College
Recruiting --> Completed Recruiting --> Active, not recruiting
- Phase classification, Enrollment change, Trial primary completion date: SOMMEDREP: Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children (clinicaltrials.gov) - Sep 29, 2016
P=N/A, N=120, Recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Phase classification: P2/3 --> P=N/A | N=280 --> 120 | Trial primary completion date: Mar 2017 --> Aug 2018
- tadalafil / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia (clinicaltrials.gov) - Sep 21, 2016
P2, N=0, Withdrawn, Sponsor: Johns Hopkins University
Phase classification: P2/3 --> P=N/A | N=280 --> 120 | Trial primary completion date: Mar 2017 --> Aug 2018 N=20 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Dec 2010 --> Aug 2009
- Trial completion, Enrollment change, Trial primary completion date: High-Tc Susceptometer to Monitor Transfusional Iron Overload (clinicaltrials.gov) - Sep 21, 2016
P2, N=99, Completed, Sponsor: Columbia University
N=20 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Dec 2010 --> Aug 2009 Recruiting --> Completed | N=190 --> 99 | Trial primary completion date: Aug 2016 --> Oct 2015
- Trial completion: A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease (clinicaltrials.gov) - Sep 19, 2016
P=N/A, N=24, Completed, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Completed | N=190 --> 99 | Trial primary completion date: Aug 2016 --> Oct 2015 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease (clinicaltrials.gov) - Sep 13, 2016
P=N/A, N=10, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Completed Suspended --> Completed | Trial primary completion date: Aug 2019 --> Sep 2016
- Trial primary completion date: Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease (clinicaltrials.gov) - Sep 2, 2016
P1, N=25, Active, not recruiting, Sponsor: The Cleveland Clinic
Suspended --> Completed | Trial primary completion date: Aug 2019 --> Sep 2016 Trial primary completion date: Aug 2016 --> Dec 2016
- Trial completion: iTransition: Patient-Provider Tools to Improve the Transition to Adult Care in Sickle Cell Disease (clinicaltrials.gov) - Aug 29, 2016
P=N/A, N=72, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Trial primary completion date: Aug 2016 --> Dec 2016 Active, not recruiting --> Completed
- plerixafor / Generic mfg.
Enrollment open: DrepaMob: Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients (clinicaltrials.gov) - Aug 26, 2016
P1/2, N=5, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment closed, Trial primary completion date: Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease (clinicaltrials.gov) - Aug 23, 2016
P1, N=25, Active, not recruiting, Sponsor: The Cleveland Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Aug 2016
- Trial completion: The Link Between Anemia and Deficits in Memory and Attention in Individuals With Sickle Cell Disease (clinicaltrials.gov) - Aug 19, 2016
P=N/A, N=120, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Aug 2016 Recruiting --> Completed
- Enrollment closed, HEOR: Decision Aid for Therapeutic Options In Sickle Cell Disease (clinicaltrials.gov) - Aug 11, 2016
P=N/A, N=120, Active, not recruiting, Sponsor: Emory University
Recruiting --> Completed Recruiting --> Active, not recruiting
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: A Phase II Trial of Regadenoson in Sickle Cell Anemia (clinicaltrials.gov) - Aug 10, 2016
P2, N=100, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Oct 2016
- Trial completion, Enrollment change: Blood Flow and Pain Crises in People With Sickle Cell Disease (clinicaltrials.gov) - Aug 5, 2016
P=N/A, N=94, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Jun 2016 --> Oct 2016 Recruiting --> Completed | N=120 --> 94
- hydroxyurea / Generic mfg.
Trial completion, Enrollment change: State Of The Art Functional Imaging In Sickle Cell Disease (clinicaltrials.gov) - Aug 3, 2016
P=N/A, N=38, Completed, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Completed | N=120 --> 94 Recruiting --> Completed | N=60 --> 38
- | NN1213 / Novo Nordisk
Trial completion: Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II (clinicaltrials.gov) - Jul 27, 2016
P=N/A, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed | N=60 --> 38 No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Induction of Stable Chimerism for Sickle Cell Anemia (clinicaltrials.gov) - Jul 27, 2016
P2, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
No longer recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia (clinicaltrials.gov) - Jul 27, 2016
P2, N=30, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
No longer recruiting --> Completed Recruiting --> Completed
- morphine sulphate / Generic mfg., hydromorphone hydrochloride / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease (clinicaltrials.gov) - Jul 11, 2016
P4, N=106, Completed, Sponsor: Duke University
Recruiting --> Completed Recruiting --> Completed | N=77 --> 106 | Trial primary completion date: Dec 2016 --> Jun 2016
- | acetylcysteine solution / Generic mfg.
Trial completion: N-Acetylcysteine in Patients With Sickle Cell Disease (clinicaltrials.gov) - Jul 5, 2016
P3, N=96, Completed, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting --> Completed | N=77 --> 106 | Trial primary completion date: Dec 2016 --> Jun 2016 Active, not recruiting --> Completed
- | hydroxyurea / Generic mfg.
Enrollment closed: NOHARM: Novel Use Of Hydroxyurea in an African Region With Malaria (clinicaltrials.gov) - Jun 28, 2016
P3, N=200, Active, not recruiting, Sponsor: Indiana University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- hydroxyurea / Generic mfg.
Trial completion: ELYSIS: Long Term Effects of Erythrocyte Lysis (clinicaltrials.gov) - Jun 27, 2016
P=N/A, N=390, Completed, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells (clinicaltrials.gov) - Jun 23, 2016
P1/2, N=25, Completed, Sponsor: Children's Hospital Los Angeles
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Aug 2015
- Enrollment change, Trial primary completion date: Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease (clinicaltrials.gov) - Jun 16, 2016
P1, N=15, Recruiting, Sponsor: University Hospital Case Medical Center
Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Aug 2015 N=20 --> 15 | Trial primary completion date: Jun 2015 --> Jun 2017
- | PF-04447943 / Pfizer
Phase classification: Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease (clinicaltrials.gov) - Jun 15, 2016
P1b, N=64, Recruiting, Sponsor: Pfizer
N=20 --> 15 | Trial primary completion date: Jun 2015 --> Jun 2017 Phase classification: P1 --> P1b
- Enrollment change: Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC) (clinicaltrials.gov) - Jun 11, 2016
P2, N=0, Withdrawn, Sponsor: Johns Hopkins University
Phase classification: P1 --> P1b N=120 --> 0
- Enrollment closed: Molecular Phenotyping of Asthma in Sickle Cell Disease (clinicaltrials.gov) - Jun 10, 2016
P=N/A, N=100, Active, not recruiting, Sponsor: Nemours Children's Clinic
N=120 --> 0 Recruiting --> Active, not recruiting
- losartan / Generic mfg.
Trial primary completion date: Losartan for Sickle Cell Kidney Disease (clinicaltrials.gov) - May 18, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2016 --> Dec 2016
- Trial completion: Evaluation of Nocturnal Enuresis and Barriers to Treatment Among Pediatric Patients With Sickle Cell Disease (clinicaltrials.gov) - May 11, 2016
P=N/A, N=250, Completed, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Apr 2016 --> Dec 2016 Recruiting --> Completed
- | ticagrelor / Generic mfg.
Enrollment open, Trial primary completion date: HESTIA 1: A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease (clinicaltrials.gov) - May 5, 2016
P2, N=40, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed Suspended --> Recruiting | Trial primary completion date: Jan 2016 --> Apr 2017
- Enrollment closed, Enrollment change, Trial primary completion date: A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease (clinicaltrials.gov) - May 2, 2016
P=N/A, N=24, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Suspended --> Recruiting | Trial primary completion date: Jan 2016 --> Apr 2017 Recruiting --> Active, not recruiting | N=89 --> 24 | Trial primary completion date: Oct 2016 --> Mar 2016
- ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Enrollment change: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease (clinicaltrials.gov) - Apr 28, 2016
P2, N=10, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | N=89 --> 24 | Trial primary completion date: Oct 2016 --> Mar 2016 Active, not recruiting --> Completed | N=25 --> 10
- | hydroxyurea / Generic mfg.
Trial completion: Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH) (clinicaltrials.gov) - Apr 12, 2016
P3, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed | N=25 --> 10 No longer recruiting --> Completed
- Enrollment closed, Trial primary completion date: Iron Mediated Vascular Disease in Sickle Cell Anemia Patients (clinicaltrials.gov) - Mar 18, 2016
P=N/A, N=150, Active, not recruiting, Sponsor: Children's Hospital Los Angeles
No longer recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2012 --> Oct 2018
- morphine sulphate / Generic mfg., hydromorphone hydrochloride / Generic mfg.
Trial primary completion date: Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease (clinicaltrials.gov) - Mar 11, 2016
P4, N=77, Recruiting, Sponsor: Duke University
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2012 --> Oct 2018 Trial primary completion date: Feb 2016 --> Dec 2016
- propranolol ER / Generic mfg.
Trial primary completion date: Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease (clinicaltrials.gov) - Feb 16, 2016
P1, N=20, Recruiting, Sponsor: University of Miami
Trial primary completion date: Feb 2016 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2017
- decitabine / Generic mfg.
Trial completion: Decitabine for High-Risk Sickle Cell Disease (clinicaltrials.gov) - Feb 9, 2016
P2, N=10, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Dec 2015 --> Dec 2017 Suspended --> Completed
- Trial completion: Exercise Capacity in Pediatric Sickle Cell Anemia (clinicaltrials.gov) - Feb 4, 2016
P=N/A, N=60, Completed, Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Suspended --> Completed Recruiting --> Completed